基本信息 产品详情 公司简介 推荐产品
网站主页 Research Grade Budoprutug
  • (Budoprutug)Biosimilar Reference Antibody-GS40107
  • (Budoprutug)Biosimilar Reference Antibody-GS40107
  • (Budoprutug)Biosimilar Reference Antibody-GS40107

1/3

(Budoprutug)Biosimilar Reference Antibody-GS40107 新品

Budoprutug
300 100μg 起订
湖北 更新日期:2026-03-12

武汉迈思生物科技有限公司

VIP1年
联系人:市场
电话:027-65523427拨打
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

英文名称:
Budoprutug
CAS号:
2720478-38-4
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Chimeric
偶联物:
靶点:
CD19
免疫原:
CD19
亚型:
IgG1 - kappa
验证方法:
(Budoprutug)Biosimilar Reference Antibody(GS40107) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

货号:GS40107

Budoprutug is a human IgG1 kappa monoclonal antibody. It is designed as a targeted therapeutic agent specifically aimed at the CD19 antigen. Its primary mechanism of action is to induce the death of malignant B cells that express this antigen by binding to CD19. As an IgG1 isotype antibody, it possesses potent immune effector functions, enabling it to mediate the clearance of B cells through Antibody-Dependent Cellular Cytotoxicity (ADCC) and/or Complement-Dependent Cytotoxicity (CDC). Budoprutug is investigated for the treatment of B cell malignancies, such as Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), with the goal of eliminating the cancerous B cell population in the body.


Budoprutug;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 1000万-5000万
经营模式 工厂,试剂,定制,服务
主营行业 抗体,蛋白组学

Budoprutug相关厂家报价

内容声明
拨打电话 立即询价